Pelthos Therapeutics Inc. (PTHS): Total Assets
$130.40M
As of 2025-12-31
$137.36M
As of 2026-06-30
n/m
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $130.40M | n/m | 2026-03-19, Balance as of period end |
| 2024-12-31 | $1.37M | n/m | 2026-03-19, Balance as of period end |
| 2023-12-31 | $96.4K | +75.0% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $55.1K | n/a | 2024-04-16, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $130.40M | n/m |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $621.33M | -28.7% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $305.88M | +42.1% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
| Alector, Inc. (ALEC) | 2025-12-31 | $293.24M | -37.4% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $221.10M | -31.9% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $175.37M | -44.0% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $228.79M | -38.4% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $79.73M | +57.1% |
Compare PTHS, RLAY, LENZ, LCTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗